VCEL - Vericel Corporation

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $60.67 DETAILS

Stock News

Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sep 15, 2026 06:41 PM • seekingalpha.com

Vericel: MACI And Regenerative Knee Cartilage

Vericel's MACI already has an established commercial base, which I think gives them an easier path for future growth. MACI's arthroscopic delivery could also help it expand among surgeons. That's why VCEL's Burlington added capacity is timely if demand indeed increases. I also like that VCEL's recently gained BARDA contract helps with its Burn Care business. VCEL also has a potential UK launch and an ankle indication in the works.

Sep 14, 2026 07:47 PM • seekingalpha.com

Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026

BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15th, 2026.

Sep 08, 2026 04:30 AM • globenewswire.com

Canada Pension Plan Investment Board Takes Position in Vericel Corporation $VCEL

Canada Pension Plan Investment Board purchased a new position in Vericel Corporation (NASDAQ: VCEL) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 13,400 shares of the biotechnology company's stock, valued at approximately $596,000. Several other hedge funds and other institutional investors also recently

Sep 02, 2026 12:17 AM • defenseworld.net

Vericel Corporation $VCEL Shares Purchased by Bank of America Corp DE

Bank of America Corp DE boosted its holdings in Vericel Corporation (NASDAQ: VCEL) by 19.7% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 1,098,771 shares of the biotechnology company's stock after buying an additional 180,761 shares during the period. Bank of America Corp DE owned

Aug 14, 2026 11:33 PM • defenseworld.net

Vericel Q2 Earnings Call Highlights

Vericel NASDAQ: VCEL reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and cash generation.

Jul 30, 2026 01:04 PM • marketbeat.com

Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript

Jul 30, 2026 08:54 AM • seekingalpha.com

Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates

Vericel Corporation (VCEL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago.

Jul 30, 2026 06:36 AM • zacks.com

Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program

Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of Directors Authorizes $200 Million Share Repurchase Program Conference Call Today at 8:30am Eastern Time BURLINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2026.

Jul 30, 2026 03:55 AM • globenewswire.com

Vericel Corporation $VCEL Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC trimmed its position in Vericel Corporation (NASDAQ: VCEL) by 3.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 678,003 shares of the biotechnology company's stock after selling 21,710 shares during the quarter. Allspring Global Investments Holdings

Jul 20, 2026 11:08 PM • defenseworld.net

Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026

BURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second quarter 2026 financial results on Thursday, July 30, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

Jul 16, 2026 04:30 AM • globenewswire.com

Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests

10,000 Common Stock shares were sold for a transaction value of $402,000 at an average price of around $40.24 per share on June 18, 2026. The sale represented 38% of Halpin's direct Common Stock holdings, reducing his direct stake from 26,248 to 16,248 shares, though he also has options.

Jun 27, 2026 08:58 AM • fool.com

Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026

BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16th, 2026.

Jun 09, 2026 04:30 AM • globenewswire.com

Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More

Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.

May 30, 2026 10:39 AM • fool.com

Vericel Q1 Earnings Call Highlights

Vericel NASDAQ: VCEL reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract.

May 08, 2026 10:10 PM • marketbeat.com

Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript

May 07, 2026 07:31 PM • seekingalpha.com

Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates

Vericel Corporation (VCEL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.

May 07, 2026 08:16 AM • zacks.com

Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91%

May 07, 2026 03:45 AM • globenewswire.com

Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 53.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

May 04, 2026 06:56 AM • zacks.com

Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026

CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

Apr 23, 2026 04:30 AM • globenewswire.com